Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients - PubMed (original) (raw)
. 2003 Apr 15;12(8):907-14.
doi: 10.1093/hmg/ddg100.
Affiliations
- PMID: 12668614
- DOI: 10.1093/hmg/ddg100
Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients
Annemieke Aartsma-Rus et al. Hum Mol Genet. 2003.
Abstract
The dystrophin deficiency leading to the severely progressing muscle degeneration in Duchenne muscular dystrophy (DMD) patients is caused by frame-shifting mutations in the DMD gene. We are developing a reading frame correction therapy aimed at the antisense-induced skipping of targeted exons from the pre-mRNA. Despite introducing a (larger) deletion, an in-frame transcript is generated that allows the synthesis of a slightly shorter, but largely functional dystrophin as found in the mostly milder Becker muscular dystrophy (BMD). We have recently demonstrated both the efficacy and high efficiency of the antisense-induced skipping of numerous exons from the DMD transcript in control muscle cells. In principle, this would restore the reading frame in over 75% of the patients reported in the Leiden DMD mutation database. In this study, we in fact demonstrate the broad therapeutic applicability of this strategy in cultured muscle cells from six DMD patients carrying different deletions and a nonsense mutation. In each case, the specific skipping of the targeted exon was induced, restoring dystrophin synthesis in over 75% of cells. The protein was detectable as soon as 16 h post-transfection, then increased to significant levels at the membrane within 2 days, and was maintained for at least a week. Finally, its proper function was further suggested by the restored membranal expression of four associated proteins from the dystrophin-glycoprotein complex. These results document important progress towards a clinically applicable, small-molecule based therapy.
Similar articles
- Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy.
Aartsma-Rus A, Bremmer-Bout M, Janson AA, den Dunnen JT, van Ommen GJ, van Deutekom JC. Aartsma-Rus A, et al. Neuromuscul Disord. 2002 Oct;12 Suppl 1:S71-7. doi: 10.1016/s0960-8966(02)00086-x. Neuromuscul Disord. 2002. PMID: 12206800 - Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells.
van Deutekom JC, Bremmer-Bout M, Janson AA, Ginjaar IB, Baas F, den Dunnen JT, van Ommen GJ. van Deutekom JC, et al. Hum Mol Genet. 2001 Jul 15;10(15):1547-54. doi: 10.1093/hmg/10.15.1547. Hum Mol Genet. 2001. PMID: 11468272 - Exon skipping for nonsense mutations in Duchenne muscular dystrophy: too many mutations, too few patients?
Yokota T, Duddy W, Echigoya Y, Kolski H. Yokota T, et al. Expert Opin Biol Ther. 2012 Sep;12(9):1141-52. doi: 10.1517/14712598.2012.693469. Epub 2012 Jun 1. Expert Opin Biol Ther. 2012. PMID: 22650324 Review. - Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations.
Aartsma-Rus A, Fokkema I, Verschuuren J, Ginjaar I, van Deutekom J, van Ommen GJ, den Dunnen JT. Aartsma-Rus A, et al. Hum Mutat. 2009 Mar;30(3):293-9. doi: 10.1002/humu.20918. Hum Mutat. 2009. PMID: 19156838 Review.
Cited by
- De novo mutations in neurological and psychiatric disorders: effects, diagnosis and prevention.
Gauthier J, Rouleau GA. Gauthier J, et al. Genome Med. 2012 Sep 25;4(9):71. doi: 10.1186/gm372. eCollection 2012. Genome Med. 2012. PMID: 23009675 Free PMC article. Review. - Targeting Alternative Splicing as a Potential Therapy for Episodic Ataxia Type 2.
Jaudon F, Baldassari S, Musante I, Thalhammer A, Zara F, Cingolani LA. Jaudon F, et al. Biomedicines. 2020 Sep 5;8(9):332. doi: 10.3390/biomedicines8090332. Biomedicines. 2020. PMID: 32899500 Free PMC article. Review. - Modulating the expression of disease genes with RNA-based therapy.
Wood M, Yin H, McClorey G. Wood M, et al. PLoS Genet. 2007 Jun;3(6):e109. doi: 10.1371/journal.pgen.0030109. PLoS Genet. 2007. PMID: 17604456 Free PMC article. Review. - Present and future of antisense therapy for splicing modulation in inherited metabolic disease.
Pérez B, Rodríguez-Pascau L, Vilageliu L, Grinberg D, Ugarte M, Desviat LR. Pérez B, et al. J Inherit Metab Dis. 2010 Aug;33(4):397-403. doi: 10.1007/s10545-010-9135-1. Epub 2010 Jun 25. J Inherit Metab Dis. 2010. PMID: 20577904 Review. - Antisense PMO found in dystrophic dog model was effective in cells from exon 7-deleted DMD patient.
Saito T, Nakamura A, Aoki Y, Yokota T, Okada T, Osawa M, Takeda S. Saito T, et al. PLoS One. 2010 Aug 18;5(8):e12239. doi: 10.1371/journal.pone.0012239. PLoS One. 2010. PMID: 20805873 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources